Dynavax Technologies Corp (DVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Dynavax Technologies Corp (DVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH81715D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dynavax Technologies Corp (Dynavax Technologies), formerly Double Helix Corporation is a biopharmaceutical company that develops product candidates for the prevention of infectious disease. The company offers medicines for prevention of infectious disease, treatment of autoimmune and inflammatory diseases, and treatment of cancer. It provides TLR technology and expertise on addressing the challenges of infectious and inflammatory diseases and cancer. The company offers adult hepatitis B vaccine that offers immune response treatment and improved protection against hepatitis B. It operates in the US and Germany. Dynavax Technologies is headquartered in Berkeley, California, the US.

Dynavax Technologies Corp (DVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Dynavax to Raise USD40 Million from Hercules Technology 11

Double Helix Raises USD0.048 Million in Seed Financing 12

Partnerships 12

Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 12

Dynavax Technologies Expands Co-Development Agreement With GlaxoSmithKline 13

AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419 14

Licensing Agreements 15

AstraZeneca Amends Research and Licensing Agreement with Dynavax 15

Equity Offering 16

Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 16

Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 18

Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 19

Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 20

Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 21

Dynavax Technologies Completes Underwritten Public Offering Of Common Stock For US$69 Million 22

Debt Offering 24

Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 24

Acquisition 25

McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 25

Dynavax Technologies Corp-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Mar 13, 2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update 29

Nov 07, 2016: Dynavax Reports Third Quarter 2016 Financial Results and Company Update 31

Aug 05, 2016: Dynavax Reports Second Quarter 2016 Financial Results 32

May 09, 2016: Dynavax Reports First Quarter 2016 Financial Results 33

Mar 08, 2016: Dynavax Reports Fourth Quarter and Year End 2015 Financial Results 34

Product News 35

10/09/2016: Dynavax Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ESMO Annual Congress 35

04/18/2016: Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101 36

Product Approvals 37

Sep 04, 2016: Dynavax Provides Regulatory Update on HEPLISAV-B 37

Aug 16, 2016: Dynavax gets November Adcomm review for hep B vaccine 38

Aug 06, 2016: Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B 39

Apr 27, 2016: Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016 40

Mar 30, 2016: Dynavax Announces FDA Acceptance for Review of Biologics License Application and PDUFA Action Date for HEPLISAV-B 41

Clinical Trials 42

Jan 05, 2017: Dynavax Provides Update on DV-281 Oncology Program 42

Jun 11, 2016: Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B, in Adults With Type 2 Diabetes at ADA Scientific Sessions 43

Apr 18, 2016: Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B 44

Apr 04, 2016: Dynavax to Present Data From Pivotal Phase 3 HEPLISAV-B Trial 45

Jan 07, 2016: Dynavax Reports Top Line Results of Phase 3 HEPLISAV-B Study 46

Jan 06, 2016: Dynavax to Host Webcast Conference Call Tomorrow to Review HEPLISAV-B Phase 3 Clinical Data 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dynavax Technologies Corp, Deals By Therapy Area, 2011 to YTD 2017 9

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Dynavax to Raise USD40 Million from Hercules Technology 11

Double Helix Raises USD0.048 Million in Seed Financing 12

Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 12

Dynavax Technologies Expands Co-Development Agreement With GlaxoSmithKline 13

AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419 14

AstraZeneca Amends Research and Licensing Agreement with Dynavax 15

Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 16

Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 18

Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 19

Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 20

Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 21

Dynavax Technologies Completes Underwritten Public Offering Of Common Stock For US$69 Million 22

Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 24

McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 25

Dynavax Technologies Corp, Key Competitors 26

Dynavax Technologies Corp, Key Employees 27

Dynavax Technologies Corp, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Dynavax Technologies Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 15985
Site License
USD 500 INR 31970
Corporate User License
USD 750 INR 47955

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com